{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026107","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.253366+00:00","generated_at":"2026-05-31T10:04:56.225148+00:00","sec_items":["3.01","8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025","bullets":["Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.","Company has 180 days (until Feb 3, 2025) to achieve MVLS >= $35M for 10 consecutive days.","Failure to regain compliance may result in delisting; Company can appeal but no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026107","json":"https://secwatch.observer/filing/0001437749-24-026107.json","markdown":"https://secwatch.observer/filing/0001437749-24-026107.md","text":"https://secwatch.observer/filing/0001437749-24-026107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/0001437749-24-026107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924026107/nrxp20240812_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:04:56.225148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}